Its March Madnessin the life sciences industry, with money pouring in faster than LeBron James on a breakaway. Heres where the big buckswentthis week.
Design Therapeutics
Having just completed a$125 million Series Bfinancing round twomonths prior,Design Therapeutics isnow gunning for a$228 million IPO. The company is developing a platform of gene-targeted chimera small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions.
Planning to sell 12 million shares between $18 and $20 apiece, the funds will be used to develop treatments for nucleotide repeat expansion disorders, including its lead program in Friedreich ataxia, which is expected to enter clinical development in the first half of 2022.
Connect Biopharma
T-Cell driven Connect took in$191.3 million during its IPO,with a potential of swelling to $219.9 million. The San Diego-based company focuses on treating chronic inflammatory diseases.The companys lead asset CBP-201 is an antibody designed to target interleukin-4 receptor alpha (IL-4R),a validated target for the treatment of several inflammatory diseases such as atopic dermatitis (AD) and asthma.
Vaccitech
AstraZenecasCOVID-19 vaccinepartnerVaccitechgained$168 million in a Series Bfinancing round.The company plans to use the funds to support its own lead candidates in oncology and infectious disease.Itsheterologous prime-boost approach has been demonstrated to drive powerful immune responses, including the leading CD8+ T cell stimulation profile in humans, to date.Vaccitech, which is a spinout of Oxford University, has three lead programs that are all in Phase I/II studies. The company is assessing VTP-300 in patients with chronic hepatitis B virus (HBV) infection. The first patient in the trial was dosed in February.
Brii Biosciences
After two antibody programs aimed at COVID-19 wereshut down due to disappointing results,BriiBiosciences is back in the saddle with a$155 million Series Cinfusion of cash.The multi-national companywill use the funds to advance its pipeline of infectious disease candidates, as well asits CNS program.Clinical studies are being conducted in multiple infectious diseases, includingHBV, COVID-19, Gram-negative bacterial infections and HIV.
Finch Therapeutics
Finch sealed the deal with NASDAQ last week, raising$125 million in its IPO. Trading under FNCH, themicrobiome therapeutics company leveraging itsHuman-First Discoveryplatform to develop a novel class of orally administered biological drugs.Lead candidate, CP101, is in late-stage clinical development for the prevention of recurrentC. difficileinfection (CDI).A partnership with Takeda has Finch advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohns disease.
AbSci
Synthetic biology companyAbSciscored$125 million crossover financingin a round led by existinginvestors and joined by new ones. Proceeds go towards the companys continued growth inR&D, along with integration and training for the deep learning AI platformAbSciacquired in January of this year.
Ikena Oncology
Another company headed to the Nasdaq just a few months after completing aSeries B raise,Ikenaplans to offer 7.8 million shares at $15 to $17 for a raise of$125 million. With five programs in the works,Ikenaannounced its TEAD inhibitor targeting the Hippo signaling pathwayhas entered IND-enabling studies.Ikenaplans to file an IND in the second half of 2021 and to initiate a Phase Iclinical trial evaluating single-agent IK-930 in biomarker-enriched patient populations.
EpimAb
Shanghai-basedEpimAbis refilling its coffers this week with the close of a$120 million Series C.Funds are earmarked to take three programs into the clinic EMB-01, -02, and 06.The lead program, EMB-01, targets EGFR andcMETon tumor cells. Currently the candidate is in Phase I/II clinical studies in both China and the US.EMB-02 hasbeen cleared for the clinic by the FDA to target checkpoint proteins PD-1 and LAG-3.EMB-06 is a T-Cell engaging bispecific targeting CD3 and BCMA with clearance to initiate trials in Australia.
Renovacor
This biotech took whatexpertsconsideran easier road to the NASDAQ by way of SPAC, a Special Purpose Acquisition Company. Merging with publicly tradedChardanHealthcare Acquisition 2 Corp,Renovacorwill join the ticker and reap the benefits of up to$116 millionfor the combined company.According to the release, proceeds will" advance its lead rare disease gene therapy program into Phase I/II clinical development and establish a pipeline of preclinical research programs to be progressed towards IND-enabling studies.
Lava Therapeutics
With hopes to enter the clinic soon, Lava is filing for a$101 million IPO.Developing a proprietary bispecific antibody platform that engages gamma-delta T cells, thecompany'sprograms are aimed at hematological and solid cancers.LAVA-051, is expected to enter a Phase I/IIaclinical study in hematologic malignancies in the first half of 2021.
Recursion Pharmaceuticals
Salt Lake Citys Recursion is ready to see its RXRX symbol up on the ticker, with hopes to raise$100 millionin its IPO.The companys Recursion Operating Systemcombines an advanced infrastructure layer to generate what we believe is one of the worlds largest and fastest-growing proprietary biological and chemical datasets. Four programs are ready to roll into Phase II trialsforfamilial adenomatous polyposis, GM2gangliosidosis, neurofibromatosis type 2, and cerebral cavernous malformation.
AktisOncology
Supported by pharma giants Bristol Myers Squibb and Novartis,AktisOncology launched last week with a$72 million Series A.Developing novel, best-in-class tumor-targeting radiopharmaceuticals,Aktis agentshave high tumor penetration but clear from other areas of the body rapidly, maximizing tumor killing while minimizing side effects.Alpha radiotherapy is the future of radiopharmaceuticals, CEO Matthew Roden said. By harnessing the power of alpha particles with nearly 1,000 times the potency of beta particles we believe our approach has the potential to deliver game-changing results for patients.
OssiumHealth
Harnessing the power of stem cells,Ossiumannounced a$63 million Series Bround. Stem cells provide life-saving therapies,andOssiumsplatform recovers, banks and transplants bone marrow rich in the valuable cells.The company said it is bringing the US deceased donor transplant ecosystem into the fight against blood cancers, inflammatory bowel disease, organ rejection, and other life-threatening diseases where stem cell science holds the promise of a cure.
Asher Bio
New targeted immunotherapy player Asher launched this week with a$55 million Series Ato move itslead engineered interleukin-2 (IL-2) therapy into human testing next year. AB248 targetsboth an immunomodulatory receptor and a marker specific for CD8-positive effector T cells. Currently in IND-enabling studiesas a monotherapy and in combination with anti-PD-L1 checkpoint inhibitors, other cancer immunotherapy and cell therapy combinations are being considered.
Gain Therapeutics
Raising$40 millionon the NASDAQ, Gain completed its IPO last week. Funds will be used to advance pipeline therapeutics for rare genetic diseases characterized by protein misfolding. Gains small molecule drugcandidatescross the blood-brain barrier and penetrate other hard-to-treat organs such as bone and cartilage, stabilize the effective enzyme to restore function and reduce toxic substrate. Disease targets the company is going after includeMorquioB, GM1gangliosidosis, Gaucher and Parkinsons disease.
Read more:
Money on the Move: March 17-23 - BioSpace
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
- Is Phenq Right For You? Review The Facts Before Making a ... - Vashon-Maury Island Beachcomber - November 27th, 2023
- Cavityn Reviews - Does It Work? Cheap Scam or Effective ... - The Daily World - November 25th, 2023
- Trend Hunting With Beautystreams At Cosmoprof Asia 2023 - BeautyMatter - November 25th, 2023
- FDA Considers First CRISPR Gene Editing Treatment That May ... - Slashdot - November 25th, 2023
- How Do Plants Determine Where the Light Is Coming From? - Lab Manager Magazine - November 25th, 2023
- Deaths From Coal Pollution Have Dropped, But Emissions May be ... - Slashdot - November 25th, 2023
- Stem cell-based therapies for stroke in newborns - Cochrane - November 23rd, 2023
- Dr Leslie on Outpatient CAR T-Cell Therapy Programs for ... - OncLive - November 23rd, 2023
- Human Milk-Based Therapy May Be Beneficial in Blood Cancers - Curetoday.com - November 23rd, 2023
- Oncological Horizons: The Synergy of Medical and Surgical ... - Cureus - November 23rd, 2023
- Human and environmental safety of carbon nanotubes across their ... - Nature.com - November 23rd, 2023
- Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted ... - BioSpace - November 23rd, 2023
- #HearTheMarsdenKids call on NHS London to reconsider cancer ... - Metro.co.uk - November 23rd, 2023
- Diagnosis and Management of Cardiovascular Risk in Patients with ... - Dove Medical Press - November 23rd, 2023
- BioLineRx Reports Third Quarter 2023 Financial Results and ... - PR Newswire - November 21st, 2023
- Why our Award Winners Beauty Box is the ultimate beauty gift (for ... - Yahoo Singapore News - November 21st, 2023
- SightCare Reviews - Is Official Website for Sight Care Legit to Try or ... - Vashon-Maury Island Beachcomber - November 21st, 2023
- Legend Biotech Reports Third Quarter 2023 Results and Recent ... - StreetInsider.com - November 21st, 2023
- Lorenzo's Oil: Can It Really Treat ALD? - Verywell Health - November 19th, 2023
- Doctor Says Living To 120 By End Of Decade Is Possible What's the Secret? - Benzinga - November 19th, 2023
- The week in pharma: action, reaction and insight week to ... - The Pharma Letter - November 19th, 2023
- Race Cannot Be Used To Predict Heart Disease, Scientists Say ... - Slashdot - November 19th, 2023
- SpaceX's Starship Reaches Outer Space Before Intentional ... - Slashdot - November 19th, 2023
- Mesenchymal Stem Cells Market is projected to reach USD 3,319 million by 2030 according to a new research r... - WhaTech Technology and Markets News - November 17th, 2023
- LMRUK: Protecting the next generation through cord blood - Charity Today News - November 17th, 2023
- Anti-aging molecule discovered that extends lifespan - Earth.com - November 17th, 2023
- Montana State researcher envisions living building materials that ... - Montana State University - November 17th, 2023
- OxyHelp Explores the Benefits of Hyperbaric Oxygen Therapy for ... - StreetInsider.com - November 15th, 2023
- Health benefits of bone marrow - Pakistan Observer - November 15th, 2023
- Evolving the standard of care: What is next for functional ... - NeuroNews International - November 15th, 2023
- Affimed Reports Third Quarter 2023 Financial Results and ... - BioSpace - November 15th, 2023
- Meet the World's First Whole-Eye Transplant Recipient - TIME - November 15th, 2023
- Calidi Biotherapeutics Reports Third Quarter 2023 Operating and ... - Business Wire - November 15th, 2023
- 10 Asia-Pacific biotech companies leading innovation in the region - Labiotech.eu - November 15th, 2023
- Fitspresso Reviews (November Update) Natural Ingredients That ... - Bainbridge Island Review - November 15th, 2023
- 2seventy bio Reports Third Quarter Financial Results and Recent ... - Business Wire - November 15th, 2023
- Japan To Create $6.6 Billion Fund To Develop Outer Space Industry ... - Slashdot - November 15th, 2023
- Be The Match, Healthcare Marketing Impact Awards 2023 - Ad Age - November 13th, 2023
- Medicare coverage saves lives. Enrolling shouldn't be this ... - Kevin MD - November 13th, 2023
- Future Ocean Foods: 36 Global Alt-Seafood Startups Form Association To Tackle Overfishing, Microplastics & More - Green Queen Media - November 13th, 2023
- Orchard Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 13th, 2023
- Celebrity doctor reveals Hollywoods hidden trend of stem cell antiaging therapies - Longevity.Technology - November 11th, 2023
- Amazon Expands Healthcare Push With One Medical Benefits For ... - Slashdot - November 11th, 2023
- Bene Meat Technologies becomes the first to receive EU approval ... - Pet Food Processing - November 11th, 2023
- FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma - Yahoo Finance - November 11th, 2023
- MaaT Pharma Provides Third Quarter 2023 Business Update and ... - Business Wire - November 11th, 2023
- IN8bio Reports Third Quarter 2023 Financial Results and Provides ... - GlobeNewswire - November 11th, 2023
- Fast Lean Pro Reviews - Overpriced or Optimal Ingredients That ... - Journal of the San Juan Islands - November 11th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - GlobeNewswire - November 11th, 2023
- Worlds first whole-eye and partial face transplant gives Arkansas man new hope - CNN - November 9th, 2023
- Glowing Fingertips And Green Eyes: First-of-Its-Kind Monkey ... - ScienceAlert - November 9th, 2023
- 10 Natural Body Scrubs That Exfoliate And Invigorate My Skin - PINKVILLA - November 9th, 2023
- CRISPR Therapeutics Provides Business Update and Reports Third ... - StreetInsider.com - November 9th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - StreetInsider.com - November 9th, 2023
Recent Comments